Cartalax (20 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Subcutaneous, once daily. Evidence note: specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection volumes within typical SC tolerability parameters.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Insert needle through the stopper; let the diluent run slowly down the vial wall to avoid foaming.
3. Gently swirl or roll until fully dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 6.67 mg/mL, 1 unit = 0.01 mL » 66.7 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at 2 to 8 °C or freeze at -20 °C for long-term stability.
• Reconstituted: refrigerate at 2 to 8 °C; avoid freeze-thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration (average ~3.5 mg/day).

Peptide Vials (Cartalax, 20 mg each):

• 8 weeks: ~10 vials. 12 weeks: ~15 vials. 16 weeks: ~20 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (10 vials): 3 bottles. 12 weeks (15 vials): 5 bottles. 16 weeks (20 vials): 6 bottles.

Alcohol Swabs:

• 16 weeks: 224 swabs (3 x 100-count boxes).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Evidence caveat: published human clinical trial data for subcutaneous Cartalax is limited; this protocol

extrapolates from preclinical studies.

How This Works

Cartalax (Ala-Glu-Asp) is classified among the Khavinson bioregulatory peptides, ultrashort peptides that may interact with DNA and modulate gene expression at nanomolar concentrations. The peptide sequence corresponds to a motif found in the alpha-1 chain of type XI collagen, a structural protein important for cartilage integrity. In preclinical fibroblast and chondrocyte culture models, Cartalax has been reported to upregulate Ki-67 (a proliferation marker), increase SIRT-1/SIRT-6 expression, reduce p53 and caspase-3 activity, and inhibit MMP-9 synthesis (an enzyme linked to extracellular matrix degradation).

Benefits & Side Effects

Observations from preclinical and clinical literature.

• May support fibroblast proliferation and reduce markers of cellular senescence in aged cell cultures.
• Preclinical data suggest modulation of extracellular matrix homeostasis via MMP-9 inhibition and

collagen-related gene expression.

• Khavinson bioregulator peptides have been described as well tolerated in observational settings; mild

injection-site reactions may occur.

• Limitations: No large-scale human RCTs; most data derive from in vitro or rodent models.

Lifestyle Factors

Complementary strategies for best outcomes.

• Support joint and connective-tissue health with adequate protein, vitamin C, and collagen precursors.
• Combine low-impact exercise and mobility work to reinforce musculoskeletal adaptations.
• Prioritize sleep and stress management to support tissue repair and recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Lin'kova NS et al. Peptide Regulation of Skin Fibroblast Functions during Aging In Vitro (Bulletin of Experimental Biology and Medicine, 2016).
2. Khavinson VK. Peptides and Ageing: bioregulatory peptide mechanisms (Neuroendocrinology Letters, 2002).